Loading news...
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Revenue Results WAYNE, Pa., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that Stuart Randle, a member of the Company's Board of Directors, has been appointed Interim President and Chief Executive Officer, effective immediately.
Teleflex Incorporated (NYSE: TFX - Get Free Report) has been given a consensus rating of "Reduce" by the twelve ratings firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and one has assigned a buy recommendation to the company.
NexGel (NASDAQ: NXGL - Get Free Report) and Teleflex (NYSE: TFX - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Profitability This table compares NexGel and Teleflex's net margins, return
Teleflex (NYSE: TFX - Get Free Report) and Veracyte (NASDAQ: VCYT - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Profitability This table compares Teleflex and Veracyte's net margins,
TFX's UroLift expansion and Barrigel traction support long-term growth, but high debt and FX headwinds keep the stock under pressure.
Teleflex Incorporated rebounded from lows after announcing a $2.03B divestiture of Acute Care, Interventional Urology, and OEM businesses. TFX will use $1B of net proceeds for share buybacks, reducing pro forma net debt to $1.5B, but revenue impact remains ambiguous. Shares now trade at 10x adjusted earnings, with market reaction positive despite uncertainty around divested revenue figures.
NEW YORK--(BUSINESS WIRE)--Montagu and Kohlberg, two leading middle-market private equity firms, today announced that they have entered into a definitive agreement to acquire Teleflex Medical OEM (the “Company”) from Teleflex Incorporated (NYSE: TFX) for $1.5 billion in a carve-out transaction. For over 40 years, Teleflex Medical OEM has developed and supplied custom-engineered interventional catheter components and sub-assemblies, as well as surgical fibers and sutures, used across fast-growin.
Medical device maker Teleflex said on Tuesday it will sell three of its business units for a total of $2.03 billion in cash.
Board of Directors authorizes new $1 billion share repurchase program Board of Directors authorizes new $1 billion share repurchase program
Teleflex (NYSE: TFX - Get Free Report) and Thermo Fisher Scientific (NYSE: TMO - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk. Institutional and Insider Ownership 95.6% of Teleflex shares
Teleflex Incorporated ( TFX ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:00 AM EST Company Participants Liam Kelly - Chairman, President & CEO Conference Call Participants Matthew Taylor - Jefferies LLC, Research Division Presentation Matthew Taylor Jefferies LLC, Research Division Great. Thanks for joining us here for our next session.
Explore Teleflex's (TFX) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Teleflex Incorporated (NYSE: TFX - Get Free Report) has been given an average rating of "Reduce" by the twelve ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the
Teleflex Incorporated ( TFX ) Discusses Strategic Rationale and Portfolio Overview of Acquired Vascular Intervention Business November 14, 2025 8:00 AM EST Company Participants Lawrence Keusch - Vice President of Investor Relations & Strategy Development Thierry Glauser Christopher Buller Liam Kelly - Chairman, President & CEO Conference Call Participants Kevin Croce Elliot Smith Patrick Wood - Morgan Stanley, Research Division Ravi Misra - Truist Securities, Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Teleflex Vascular Intervention Investor Meeting. [Operator Instructions] Please note that this conference call is being recorded and will be available on the company's website for replay shortly.
WAYNE, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) is scheduled to speak at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025, at 10:00 a.m. (GMT).
Teleflex posts strong Q3 earnings and revenue beats but trims 2025 outlook, sending shares slightly lower.
Teleflex Incorporated (NYSE:TFX) reported better-than-expected earnings for the third quarter on Thursday.
Teleflex Incorporated ( TFX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lawrence Keusch - Vice President of Investor Relations & Strategy Development Liam Kelly - Chairman, President & CEO John Deren - Executive VP & CFO Conference Call Participants Michael Matson - Needham & Company, LLC, Research Division Matthew Taylor - Jefferies LLC, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Ravi Misra - Truist Securities, Inc., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Patrick Wood - Morgan Stanley, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Teleflex Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded and will be available on the company's website for replay shortly.